Implementation of Telemedicine Delivery of Medications for Opioid Use Disorder in Pennsylvania Treatment Programs During COVID-19

Journal of Addiction Medicine, Journal Year: 2022, Volume and Issue: 17(2), P. e110 - e118

Published: Sept. 19, 2022

Introduction Temporary policy changes during the coronavirus disease 2019 pandemic facilitated rapid expansion of medication for opioid use disorder via telemedicine (tele-MOUD). Evidence tele-MOUD best practices and its impact on treatment engagement retention remains limited. This quality improvement initiative compared implementation among Pennsylvania (MOUD) programs, evaluated sociodemographic characteristics patients using tele-MOUD, described trends in patient retention. Methods Five health systems with MOUD programs completed questionnaires regarding their models provided aggregated data in-person visits 2020. Three monthly appointment (scheduled, completed, no-show, visits) over period which scaled up. Results Differences protocols related to provision inductions, eligibility operationalization remote drug testing. Across 88% prescribers conducted appointments, 50% used We observed differences, a greater proportion female, White, non-Hispanic tele-MOUD. data, overall enrollment increased, new remained relatively constant. Engagement suggested temporary decline no-show appointments that aligned escalation one program. Conclusions Tele-MOUD protocol differences indicate need research inform evidence-based guidance. Findings suggest largely engaged retained as was implemented but reveal inequities use, highlighting efforts overcome technology access barriers avoid exacerbating disparities access.

Language: Английский

---

Qualitative content analysis of public responses to an FDA inquiry on the impact of scheduling changes to kratom

International Journal of Drug Policy, Journal Year: 2022, Volume and Issue: 108, P. 103817 - 103817

Published: Aug. 9, 2022

Language: Английский

---

Using Reddit as a recruitment strategy for addiction science research

Journal of Substance Use and Addiction Treatment, Journal Year: 2023, Volume and Issue: 148, P. 209011 - 209011

Published: March 15, 2023

Language: Английский

---

Pandemic telehealth flexibilities for buprenorphine treatment: A synthesis of evidence and policy implications for expanding opioid use disorder care in the U.S

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: March 17, 2023

Abstract Buprenorphine is a highly effective treatment for opioid use disorder and critical tool addressing the worsening U.S. overdose crisis. However, multiple barriers to - including stringent federal regulations have historically made this medication hard reach many who need it. In 2020, under COVID-19 Public Health Emergency, regulators substantially changed access buprenorphine by allowing prescribers initiate patients on via telehealth without first evaluating them in person. As Emergency set expire May of 2023, Congress agencies can leverage extensive evidence from studies conducted during wake pandemic make evidencebased decisions regulation going forward. To aid policy makers, review synthesizes interprets peer-reviewed research effect flexibilities uptake implementation telehealth, its impact OUD patient prescriber experiences, health outcomes. Overall, our finds that took advantage audio-only option, with wide range benefits few downsides. result, regulators—including Congress—should continue non-restricted initiation.

Language: Английский

---

First-hand accounts of structural stigma toward people who use opioids on Reddit

Social Science & Medicine, Journal Year: 2024, Volume and Issue: 347, P. 116772 - 116772

Published: March 16, 2024

Language: Английский

---